Fragment-Based Drug Design Targeting the SARS-CoV-2 Main Protease: A Computational Approach
DOI:
https://doi.org/10.5281/zenodo.22638077Keywords:
fragment-based drug design, SARS-CoV-2 main protease, crystallographic fragment screening, COVID Moonshot, nirmatrelvirAbstract
Background: The SARS-CoV-2 main protease (Mpro, 3CLpro) is essential for viral polyprotein processing and has no human
homologue, making it a prime antiviral target . Objective: This review synthesises published fragment-based drug design (FBDD)
efforts against Mpro, from early crystallographic screens to the clinically approved inhibitor nirmatrelvir. Methods: A narrative
review of crystallographic fragment-soaking campaigns (including the Diamond Light Source XChem/COVID Moonshot effort),
virtual/computational FBDD studies, and SAR work targeting Mpro, drawing on PubMed, Google Scholar, Crossref and bioRxiv.
Findings: Crystallographic screening of the apo Mpro active site identified dozens of weak-binding fragments that seeded
open-science medicinal chemistry campaigns ; the COVID Moonshot effort progressed these into low-nanomolar noncovalent
inhibitors through iterative merging and growing . Parallel computational approaches, including ultralarge virtual screening and
free-energy-guided molecular sculpting, converged on similar chemotypes . These insights informed peptidomimetic optimisation
culminating in nirmatrelvir, validated in the EPIC-HR trial . Conclusions: FBDD, anchored by high-throughput crystallography
and computation, provided a rapid route from fragment hit to approved oral antiviral, while resistance mutations highlight the
value of fragment-derived alternative binding sites .
References
Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Zhao Q, Zhou Z, Pei D, Ziebuhr J, Hilgenfeld R, Yuen KY, Wong L, Gao G, Chen S, Chen Z, Ma D, Bartlam M, Rao Z. Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases. PLoS Biol. 2005;3(10):e324. doi:10.1371/journal.pbio.0030324. PMID:16128623.
Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020;30(17):127377. doi:10.1016/j.bmcl.2020.127377. PMID:32738988.
Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, Resnick E, Strain-Damerell C, Aimon A, Ábrányi-Balogh P, Brandão-Neto J, Carbery A, Davison G, Dias A, Downes TD, Dunnett L, Fairhead M, Firth JD, Jones SP, Keeley A, Keserü GM, Klein HF, Martin MP, Noble MEM, O'Brien P, Powell A, Reddi RN, Skyner R, Snee M, Waring MJ, Wild C, London N, von Delft F, Walsh MA. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020;11:5047. doi:10.1038/s41467-020-18709-w. PMID:33028810.
Fearon D, Powell A, Fearon D, Collins PM, Talon R, Krojer T, Skyner R, Brandao-Neto J, Dunnett L, Dias A, Aimon A, Pearce NM, Wild C, Gorrie-Stone T, von Delft F. Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source. J Vis Exp. 2021;(171):e62414. doi:10.3791/62414. PMID:34125095.
Günther S, Reinke PYA, Fernández-García Y, Lieske J, Lane TJ, Ginn HM, Koua FHM, Ehrt C, Ewert W, Oberthuer D, Yefanov O, Meier S, Lorenzen K, Krichel B, Kopicki JD, Gelisio L, Brehm W, Dunkel I, Seychell B, Gieseler H, Norton-Baker B, Escudero-Pérez B, Domaracky M, Saouane S, Tolstikova A, White TA, Hänle A, Groessler M, Fleckenstein H, Trost F, Galchenkova M, Gevorkov Y, Li C, Awel S, Peck A, Barthelmess M, Schlünzen F, Xavier PL, Werner N, Andaleeb H, Ullah N, Falke S, Srinivasan V, França BA, Schwinzer M, Brognaro H, Rogers C, Melo D, Zaitseva-Doyle JJ, Knoska J, Peña-Murillo GE, Mashhour AR, Hennicke V, Fischer P, Hakanpää J, Meyer J, Gribbon P, Ellinger B, Kuzikov M, Wolf M, Beccari AR, Bourenkov G, von Stetten D, Pompidor G, Bento I, Panneerselvam S, Karpics I, Schneider TR, Garcia-Alai MM, Niebling S, Günther C, Schmidt C, Schubert R, Han H, Boger J, Monteiro DCF, Zhang L, Sun X, Pletzer-Zelgert J, Wollenhaupt J, Feiler CG, Weiss MS, Schulz E, Mehrabi P, Karničar K, Usenik A, Loboda J, Tidow H, Chari A, Hilgenfeld R, Uetrecht C, Cox R, Zaliani A, Beck T, Rarey M, Günther S, Turk D, Hinrichs W, Chapman HN, Pearson AR, Betzel C, Meents A. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. 2021;372(6542):642-646. doi:10.1126/science.abf7945. PMID:33811162.
Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC, The COVID Moonshot Consortium, Chodera JD, Lee AA, London N, von Delft A, von Delft F. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023;382(6671):eabo7201. doi:10.1126/science.abo7201. PMID:37943932.
Lockbaum GJ, Reyes AC, Lee JM, Tilvawala R, Nalivaika EA, Ali A, Kurt Yilmaz N, Thompson PR, Schiffer CA. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Viruses. 2021;13(2):174. doi:10.3390/v13020174. PMID:33499129.
Teli DM, Patel B, Chhabria MT. Fragment-based design of SARS-CoV-2 Mpro inhibitors. Struct Chem. 2022;33(6):2155-2168. doi:10.1007/s11224-022-02031-w.
Luttens A, Gullberg H, Abdurakhmanov E, Vo DD, Akaberi D, Talibov VO, Nekhotiaeva N, Vangeel L, De Jonghe S, Jochmans D, Krambrich J, Tas A, Lundgren B, Gravenfors Y, Craig AJ, Atilaw Y, Sandström A, Moodie LWK, Lundkvist Å, van Hemert MJ, Neyts J, Lennerstrand J, Kihlberg J, Sandberg K, Danielson UH, Carlsson J. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. J Am Chem Soc. 2022;144(7):2905-2920. doi:10.1021/jacs.1c08402. PMID:35142215.
Zhang CH, Stone EA, Deshmukh M, Ippolito JA, Ghahremanpour MM, Tirado-Rives J, Spasov KA, Zhang S, Takeo Y, Kudalkar SN, Liang Z, Isaacs F, Lindenbach B, Miller SJ, Anderson KS, Jorgensen WL. Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations. ACS Cent Sci. 2021;7(3):467-475. doi:10.1021/acscentsci.1c00039. PMID:33791427.
Gao K, Wang R, Chen J, Tepe JJ, Huang F, Wei GW. Perspectives on SARS-CoV-2 Main Protease Inhibitors. J Med Chem. 2021;64(23):16922-16955. doi:10.1021/acs.jmedchem.1c00409. PMID:34798775.
Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A, Di L, Eng H, Ferre R, Gajiwala KS, Gibson SA, Greasley SE, Hurst BL, Kadar EP, Kalgutkar AS, Lee JC, Lee J, Liu W, Mason SW, Noell S, Novak JJ, Obach RS, Ogilvie K, Patel NC, Pettersson M, Rai DK, Reese MR, Sammons MF, Sathish JG, Singh RSP, Steppan CM, Stewart AE, Tuttle JB, Updyke L, Verhoest PR, Wei L, Yang Q, Zhu Y. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593. doi:10.1126/science.abl4784. PMID:34726479.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM. Nirmatrelvir for Nonhospitalized Adults with COVID-19. N Engl J Med. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542. PMID:35172054.
Iketani S, Mohri H, Culbertson B, Hong SJ, Duan Y, Luck MI, Annavajhala MK, Guo Y, Sheng Z, Uhlemann AC, Goff SP, Sabo Y, Yang H, Chavez A, Ho DD. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2022;613(7944):558-564. doi:10.1038/s41586-022-05514-2. PMID:36351451.
Alzyoud L, Ghattas MA, Atatreh N. Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents. Drug Des Devel Ther. 2022;16:2463-2478. doi:10.2147/DDDT.S370574. PMID:35937632.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7. PMID:32015507.
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289-293. doi:10.1038/s41586-020-2223-y. PMID:32272481.
Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368(6489):409-412. doi:10.1126/science.abb3405. PMID:32198291.
Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, von Brunn A, Leyssen P, Lanko K, Neyts J, de Wilde A, Snijder EJ, Liu H, Hilgenfeld R. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. J Med Chem. 2020;63(9):4562-4578. doi:10.1021/acs.jmedchem.9b01828. PMID:31916773.
Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem. 2009;1(3):187-192. doi:10.1038/nchem.217.
Congreve M, Carr R, Murray C, Jhoti H. A 'Rule of Three' for fragment-based lead discovery? Drug Discov Today. 2003;8(19):876-877. doi:10.1016/S1359-6446(03)02831-9. PMID:14554012.
Kneller DW, Phillips G, Weiss KL, Pant S, Zhang Q, O'Neill HM, Coates L, Kovalevsky A. Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography. J Biol Chem. 2020;295(50):17365-17373. doi:10.1074/jbc.AC120.016154. PMID:33060199.
Gossen J, Albani S, Hanke A, Joseph BP, Bergh C, Kuzikov M, Costanzi E, Manelfi C, Storici P, Gribbon P, Beccari AR, Talarico C, Spyrakis F, Lindahl E, Zaliani A, Carloni P, Wade RC, Musiani F, Kokh DB, Rossetti G. A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics. ACS Pharmacol Transl Sci. 2021;4(3):1079-1095. doi:10.1021/acsptsci.0c00215. PMID:34151208.
Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, Saffran HA, McKay RT, van Belkum MJ, Joyce MA, Young HS, Tyrrell DL, Vederas JC, Lemieux MJ. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2020;11:4282. doi:10.1038/s41467-020-18096-2. PMID:32855413.
Kirsch P, Hartman AM, Hirsch AKH, Empting M. Concepts and Core Principles of Fragment-Based Drug Design. Molecules. 2019;24(23):4309. doi:10.3390/molecules24234309. PMID:31779114.
Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov. 2016;15(9):605-619. doi:10.1038/nrd.2016.109. PMID:27417849.
